FeesSafety
Pluang+

Ethena Pay launches Earn+ vault offering up to 12% APY with high leverage but risks hidden by price feed setup.

Protocol Fundamentals
29 Oct 2026, 14:14 WIB
Blockonomi
View Source
Neutral
Ethena Pay launches Earn+ vault offering up to 12% APY with high leverage but risks hidden by price feed setup.

Ethena Pay introduced Earn+, a new yield product offering up to 12% APY by leveraging USDe and USDT at about 11 times leverage through Aave on Avalanche. The product uses USDe as collateral and borrows USDT, but the price feed for USDe tracks USDT, potentially masking drops in USDe's value and exposing users to significant losses. For example, a 2% drop in USDe value could wipe out 22% of a user's equity before fees. Borrowing costs and fees also impact returns, with withdrawal requests processed within 24 hours but possibly delayed. Ethena Pay caps deposits and has risk controls, but investors should be cautious of the leverage and oracle risks involved.

Ethena Pay's new Earn+ vault features up to 12% APY with about 11x leverage on USDe and USDT via Aave. For readers following the broader crypto market, here is Pluang's snapshot as of Oct 29, 2026 17:53 WIB: out of 50 major cryptocurrencies, 7 rose and 42 fell. Notable movers include EOS at Rp12.649 (+8.13%), BAT at Rp2.522 (-7.89%) with 100% buy order activity, and BCH at Rp5.114.233 (-6.65%) with 58% buy order activity and a typical hold time of 69 days.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App